Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
131,516,365
-
Number of holders
-
381
-
Total 13F shares, excl. options
-
109,361,699
-
Shares change
-
+1,355,990
-
Total reported value, excl. options
-
$15,431,272,628
-
Value change
-
+$204,818,578
-
Put/Call ratio
-
61.8%
-
Number of buys
-
193
-
Number of sells
-
-142
-
Price
-
$141.19
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q1 2021
450 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q1 2021.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 381 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 109,361,699 shares
of 131,516,365 outstanding shares and own 83.2% of the company stock.
Largest 10 shareholders include FMR LLC (17,549,900 shares), VANGUARD GROUP INC (10,585,821 shares), BAILLIE GIFFORD & CO (10,074,963 shares), WELLINGTON MANAGEMENT GROUP LLP (9,147,950 shares), BlackRock Inc. (9,012,485 shares), PRICE T ROWE ASSOCIATES INC /MD/ (5,575,213 shares), Dodge & Cox (4,321,627 shares), STATE STREET CORP (2,630,856 shares), JPMORGAN CHASE & CO (2,178,401 shares), and MORGAN STANLEY (1,785,953 shares).
This table shows the top 381 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.